Company intelligence / Profile preview

TargetSite Therapeutics

New Haven, Connecticut, United Statesventures.yale.edu ↗

Ownership: Private
Development stage: Preclinical

Overview

TargetSite Therapeutics is developing a differentiated oligonucleotide therapeutic platform targeting pro-inflammatory cytokines, with a focus on diseases of high unmet need such as idiopathic pulmonary fibrosis. The company is in the preclinical stage, leveraging discoveries from Yale University to build its pipeline around novel RNA-based approaches. No clinical results have been published yet.

Therapeutic areas: PulmonologyImmunology
Modalities: Oligonucleotides (including miRNA-targeted and mRNA-targeted therapeutics)
Industry: Biotech

Drug pipeline

3 assets

TSB-IL17A

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Yale University (academic partner/foundational research source)

Beyond the preview

Go deeper on TargetSite Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TargetSite Therapeutics.

Explore the full profile